nach oben

Erschienen in:

26.04.2021 | Cohort Studies

Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study

verfasst von: Yuichi Maeda, Toru Hirano, Kosuke Ebina, Ryota Hara, Motomu Hashimoto, Wataru Yamamoto, Kosaku Murakami, Takuya Kotani, Kenichiro Hata, Yonsu Son, Hideki Amuro, Akira Onishi, Sadao Jinno, Masaki Katayama, Atsushi Kumanogoh

Erschienen in: Rheumatology International | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

We aimed to investigate the efficacy of anti-IL-6 receptor antibody (aIL-6) and other biologic disease-modifying antirheumatic drugs (bDMARDs), such as TNF inhibitor and CTLA4-Ig in the treatment of rheumatoid arthritis (RA) in patients with knee joint involvement.

Methods

We retrospectively analyzed 1059 treatment courses of patients with RA who visited our hospitals and were treated with bDMARDs. We categorized them into two groups, with or without knee joint involvement. We investigated the clinical disease activity index (CDAI) at baseline and 12 weeks after the initiation of bDMARDs. We compared the improvement of the markers between aIL-6 and other bDMARDs.

Results

Treatment with aIL-6 significantly increased ΔCDAI (n = 91, 15.4 ± 1.1; mean ± SEM) in patients with knee joint involvement, compared to other bDMARDs (n = 232, 11.0 ± 0.7) at 12 weeks (P = 0.006). Following the multivariate analysis adjusted by the CDAI levels at baseline, age, gender, concomitant use of methotrexate, and the first use of bDMARDs, ΔCDAI levels were significantly higher in aIL-6, compared to other bDMARDs (P = 0.02). However, there was no significant difference in ΔCDAI improvement between aIL-6 (n = 162, 5.9 ± 0.6) and other bDMARDs (n = 573, 6.2 ± 0.4) in patients without swollen knee joints. ΔCDAI levels were equally increased in patients with shoulder and elbow joint involvement.

Conclusion

aIL-6 was more effective in the patients with RA and knee joint involvement, compared to other bDMARDs.

Nur mit Berechtigung zugänglich

Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376(9746):1094–1108. https://doi.org/10.1016/s0140-6736(10)60826-4CrossRefPubMed

Maeda Y, Kurakawa T, Umemoto E, Motooka D, Ito Y, Gotoh K et al (2016) Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine. Arthritis Rheumatol 68(11):2646–2661. https://doi.org/10.1002/art.39783CrossRefPubMed

Kishikawa T, Maeda Y, Nii T, Motooka D, Matsumoto Y, Matsushita M et al (2020) Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. Ann Rheum Dis 79(1):103–111. https://doi.org/10.1136/annrheumdis-2019-215743CrossRefPubMed

Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K et al (2014) Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506(7488):376–381. https://doi.org/10.1038/nature12873CrossRefPubMed

Hashimoto M, Yamazaki T, Hamaguchi M, Morimoto T, Yamori M, Asai K et al (2015) Periodontitis and Porphyromonas gingivalis in preclinical stage of arthritis patients. PLoS ONE 10(4):e0122121. https://doi.org/10.1371/journal.pone.0122121CrossRefPubMedPubMedCentral

Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T et al (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66(9):1162–1167. https://doi.org/10.1136/ard.2006.068064CrossRefPubMedPubMedCentral

Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320(13):1360–1372. https://doi.org/10.1001/jama.2018.13103CrossRefPubMed

Narazaki M, Tanaka T, Kishimoto T (2017) The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Rev Clin Immunol 13(6):535–551. https://doi.org/10.1080/1744666x.2017.1295850CrossRefPubMed

Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Pethö-Schramm A, Bernasconi C et al (2016) Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388(10042):343–355. https://doi.org/10.1016/s0140-6736(16)30363-4CrossRefPubMed

10.

Linn-Rasker SP, van der Helm-van Mil AH, Breedveld FC, Huizinga TW (2007) Arthritis of the large joints—in particular, the knee—at first presentation is predictive for a high level of radiological destruction of the small joints in rheumatoid arthritis. Ann Rheum Dis 66(5):646–650. https://doi.org/10.1136/ard.2006.066704CrossRefPubMed

11.

Nakagawa J, Koyama Y, Kawakami A, Ueki Y, Tsukamoto H, Horiuchi T et al (2017) A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study. Arthritis Res Ther 19(1):185. https://doi.org/10.1186/s13075-017-1387-9CrossRefPubMedPubMedCentral

12.

Lansbury J, Haut DD (1956) Quantitation of the manifestations of rheumatoid arthritis. 4. Area of joint surfaces as an index to total joint inflammation and deformity. Am J Med Sci. 232(2):150–155CrossRefPubMed

13.

Hashimoto M, Furu M, Yamamoto W, Fujimura T, Hara R, Katayama M et al (2018) Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther 20(1):165. https://doi.org/10.1186/s13075-018-1673-1CrossRefPubMedPubMedCentral

14.

Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K et al (2020) Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther 22(1):142. https://doi.org/10.1186/s13075-020-02232-wCrossRefPubMedPubMedCentral

15.

Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K et al (2020) Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis—the ANSWER cohort study. Clin Rheumatol 39(9):2563–2572. https://doi.org/10.1007/s10067-020-05015-5CrossRefPubMed

16.

Jinno S, Onishi A, Dubreuil M, Akashi K, Hashimoto M, Yamamoto W et al (2020) Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study. Rheumatol Int. https://doi.org/10.1007/s00296-020-04660-yCrossRefPubMed

17.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324. https://doi.org/10.1002/art.1780310302CrossRefPubMed

18.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581. https://doi.org/10.1002/art.27584CrossRefPubMed

19.

Thompson PW, Silman AJ, Kirwan JR, Currey HL (1987) Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. Arthritis Rheum 30(6):618–623. https://doi.org/10.1002/art.1780300603CrossRefPubMed

20.

Lansbury J (1968) Clinical appraisal of the activity index as a measure of rheumatoid activity. Arthritis Rheum 11(4):599–604. https://doi.org/10.1002/art.1780110411CrossRefPubMed

21.

Holt I, Cooper RG, Hopkins SJ (1991) Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur J Clin Investig 21(5):479–484. https://doi.org/10.1111/j.1365-2362.1991.tb01398.xCrossRef

22.

Chen DY, Hsieh TY, Chen YM, Hsieh CW, Lan JL, Lin FJ (2009) Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease. Gerontology 55(3):250–258. https://doi.org/10.1159/000164393CrossRefPubMed

23.

Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M (1995) Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 38(7):969–975. https://doi.org/10.1002/art.1780380713CrossRefPubMed

24.

Sasaki S, Iwata H, Ishiguro N, Obata K, Miura T (1994) Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 13(2):228–233. https://doi.org/10.1007/bf02249017CrossRefPubMed

25.

Gorai M, Ogasawara M, Matsuki Y, Yamada Y, Murayama G, Sugisaki N et al (2014) Weighting with the Lansbury Articular Index improves the correlation of ultrasound score with serum matrix metalloproteinase-3 level in rheumatoid arthritis patients. Mod Rheumatol 24(6):915–919. https://doi.org/10.3109/14397595.2014.888794CrossRefPubMed

26.

Lipina M, Makarov M, Makarov S, Novikov A (2017) The degree of cartilage degradation assessed by serum biomarker levels changes after arthroscopic knee synovectomy in rheumatoid arthritis patients. Int Orthop 41(11):2259–2264. https://doi.org/10.1007/s00264-017-3634-8CrossRefPubMed

27.

Kobayashi A, Naito S, Enomoto H, Shiomoi T, Kimura T, Obata K et al (2007) Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med 131(4):563–570. https://doi.org/10.1043/1543-2165(2007)131[563:Slomms]2.0.Co;2CrossRefPubMed

28.

Wang J, Devenport J, Low JM, Yu D, Hitraya E (2016) Relationship between baseline and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care Res (Hoboken) 68(6):882–885. https://doi.org/10.1002/acr.22765CrossRef

29.

Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B et al (2010) EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis 69(3):483–489. https://doi.org/10.1136/ard.2009.113100CrossRefPubMed

30.

Hussain SM, Neilly DW, Baliga S, Patil S, Meek R (2016) Knee osteoarthritis: a review of management options. Scott Med J 61(1):7–16. https://doi.org/10.1177/0036933015619588CrossRefPubMed

Titel: Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study
verfasst von: Yuichi Maeda
Toru Hirano
Kosuke Ebina
Ryota Hara
Motomu Hashimoto
Wataru Yamamoto
Kosaku Murakami
Takuya Kotani
Kenichiro Hata
Yonsu Son
Hideki Amuro
Akira Onishi
Sadao Jinno
Masaki Katayama
Atsushi Kumanogoh
Publikationsdatum: 26.04.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Rheumatology International / Ausgabe 7/2021
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-021-04862-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study